TLR2 and breast carcinoma: The binding of extracellular HMGB1 to TLR2/4 activates MyD88‐dependent NF‐κB/STAT3 signaling in breast cancer cells, driving epithelial‒mesenchymal transition and chemoresistance, while simultaneously polarizing TAMs toward the M2 phenotype.